Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Atossa Therapeutics, Inc. - Common Stock (NQ:ATOS)

0.9254 +0.0054 (+0.59%)
Streaming Delayed Price Updated: 12:28 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Atossa Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
NioCorp and Atossa Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
Atossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
This Excelerate Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
 
Via Benzinga
Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22
Via ACCESS Newswire
Atossa Therapeutics and Ainos Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
MicroMarvel - Atossa Therapeutics
Atossa Therapeutics, a biopharmaceutical company focused on developing medicines in oncology, has a lead program in Phase II clinical trials for breast cancer, and 100% technical buy signals 
Via Talk Markets
Atossa Therapeutics backing Endoxifen in the fight against breast cancer
--News Direct-- 
Via News Direct
Earnings Scheduled For March 25, 2025
 
Via Benzinga
Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
ATOS Stock Earnings: Atossa Therapeutics Beats EPS for Q2 2024
ATOS stock results show that Atossa Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
3 Dirt-Cheap Drug Developers With Blockbuster Potential
These are three of the best cheap drug developer stocks for investors to keep an eye as their growth could be imminent. 
Via InvestorPlace
3 Penny Stock Moonshots with 300%+ Upside Potential by 2025
If you understand the risks of penny stocks with upside, you may want to investigate these three stocks today. 
Via InvestorPlace
Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar
These are the biotech stocks to buy for a meme rally as they represent companies with positive impending news related to clinical trials. 
Via InvestorPlace
3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off
With the innovation space possibly getting overstretched, these biotech stocks to buy could benefit from a sector rotation. 
Via InvestorPlace
Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024
With new innovation, millions of retiring baby boomers, and an increase in mergers, biotech stocks to buy have a good deal of upside ahead. 
Via InvestorPlace
ATOS Stock Earnings: Atossa Therapeutics Beats EPS for Q1 2024
ATOS stock results show that Atossa Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Shhh! 3 Secret Penny Stocks Flying Below Wall Street’s Radar
Under-the-radar penny stocks can be some of the most rewarding investments on the market. Here are three to consider. 
Via InvestorPlace
ATOS Stock Earnings: Atossa Therapeutics Misses EPS for Q4 2023
ATOS stock results show that Atossa Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Catalyst Countdown: 3 Biotech Stocks With Upcoming News That Could Move the Market
In the volatile world of biotech stocks, keeping an eye on the news is critical. Here are three companies to look out for. 
Via InvestorPlace
This Drug Developer Is Dedicated To "Transforming The Breast Cancer Paradigm"
Dr. Steven Quay MD, PhD, President & CEO of Atossa Therapeutics Inc. (NASDAQ: ATOS) was recently interviewed by Benzinga. 
Via Benzinga
Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers - Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment
Via ACCESSWIRE
Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers – Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment
One in eight women will be diagnosed with breast cancer during 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Breast Cancer-Focused Atossa Therapeutics Can Possibly Change Treatment Paradigm: Analyst
Cantor Fitzgerald has initiated coverage of Atossa Therapeutics Inc (NASDAQ: ATOS) with an Overweight rating and  
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2023
 
Via Benzinga
Could Anixa Biosciences (NASDAQ: ANIX) Be Developing The Vaccine To End One Of The Deadliest Types Of Breast Cancer?
Cancer is a disease that affects millions of people around the world. Historically, cancer vaccines have not been very successful in treating or preventing the disease. However, recent research on the... 
Via Benzinga
50% Of Women Have Elevated Breast Density, Which Significantly Decreases the Effectiveness of Mammography - Atossa Therapeutics Is Looking To Ensure Earlier, Accurate Diagnosis
Via ACCESSWIRE
50% Of Women Have Elevated Breast Density, Which Significantly Decreases The Effectiveness Of Mammography – Atossa Therapeutics Is Looking To Ensure Earlier, Accurate Diagnosis
One in eight women will be diagnosed with breast cancer during 
Via Benzinga
3 Penny Stocks to Make Your ‘Get Rich’ Dreams Come True
When it comes to potentially profitable penny stocks, some can create unimaginable fortunes for patient investors. Others, not so much. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.